LEVOCLOPERASTINE IS AN ANTITUSSIVE WITH DISTINCT PHARMACOLOGICAL PROFILE FROM THAT OF THE RACEMIC DL-CLOPERASTINE. IT HAS A DUAL MECHANISM OF ACTION, WHERE THE DRUG ACTS ON BOTH THE CENTRAL BULBAR COUGH CENTRE AND ON PERIPHERAL RECEPTORS IN THE TRACHEOBRONCHIAL TREE. ITS ANTITUSSIVE EFFECT LIKE REDUCTION IN INTENSITY AND FREQUENCY OF COUGH ARE REPORTED IN PATIENTS OF ALL AGES, AFTER THE FIRST DAY OF TREATMENT. IT REDUCES NIGHT TIME AWAKENINGS AND IRRITABILITY IN CHILDREN; WHILE IN ADULTS, IT IS ALSO EFFECTIVE IN TREATING COUGH DUE TO ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR USAGE. THE OVERALL EFFICACY OF LEVOCLOPERASTINE IN TREATING COUGH, BRONCHOSPASM AND RELATED SYMPTOMS IS CONTRIBUTED TO THE PERIPHERAL EFFECTS RELATED TO ITS ANTIHISTAMINERGIC, ANTISEROTONERGIC AND MUSCLE-RELAXANT PROPERTIES.